- Home
- RCS vs ACHV Comparison
RCS vs ACHV Comparison
Compare RCS & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | ACHV |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.6M | 233.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | RCS | ACHV |
|---|---|---|
| Price | $5.53 | $4.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 133.6K | ★ 327.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | ★ 17.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $1.84 |
| 52 Week High | $8.00 | $6.03 |
Technical Indicators
Market Signals| Indicator | RCS | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 47.21 |
| Support Level | $5.56 | $4.24 |
| Resistance Level | $5.98 | $4.78 |
| Average True Range (ATR) | 0.12 | 0.22 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 37.04 | 39.01 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.